Article Text

PDF
The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination
  1. L B S Gelinck1,
  2. A E van der Bijl2,
  3. W E P Beyer3,
  4. L G Visser1,
  5. T W J Huizinga2,
  6. R A van Hogezand4,
  7. G F Rimmelzwaan3,
  8. F P Kroon1
  1. 1
    Department of Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands
  2. 2
    Department of Rheumatology, LUMC
  3. 3
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
  4. 4
    Department of Gastro-Enterology, LUMC
  1. L B S Gelinck, MD, Department of Infectious Diseases, C05-P, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; L.B.S.Gelinck{at}LUMC.nl

Abstract

Objectives: The effect of anti-tumour necrosis factor (TNF) therapy on the antibody responses to vaccines is the subject of ongoing debate. Therefore, we investigated the effect of the three currently available anti-TNF agents on influenza vaccination outcomes in a patient population with long-standing disease.

Methods: In a prospective cohort study, we assessed the antibody response upon influenza vaccination in 112 patients with long-standing autoimmune disease treated with immunosuppressive medication either with anti-TNF (etanercept, adalimumab or infliximab; n = 64) or without anti-TNF (n = 48) and a control group of 18 healthy individuals. Antibody responses were determined by haemagglutination inhibition assay, before and 4 weeks after vaccination.

Results: The proportion of individuals with a protective titre (⩾40) after vaccination was large (80–94%) and did not significantly differ between the three groups. Post-vaccination geometric mean antibody titres against influenza (A/H3N2 and B) were significantly lower in the 64 patients treated with anti-TNF compared with the 48 patients not receiving anti-TNF, and the healthy controls.

Conclusions: The antibody response to influenza vaccination in patients treated with anti-TNF is only modestly impaired. The proportion of patients that achieves a protective titre is not significantly diminished by the use of TNF blocking therapies.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.